Interestingly, when we looked for the pathways with significant interaction (pathways in Table 2) among the total list of pathways dysregulated in CRC in general (presented in Table 1), most of the top-ranking pathways in the combined list, in fact, were the pathways with significant interaction with KRAS mutation (see the pathways highlighted in the Table 1). The gene discussed is KRAS; the disease is colorectal carcinoma.